| Chengzhi, Zhou |
NCT06331650: A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 30 | RoW | cadonilimab | Guangzhou Institute of Respiratory Disease | Non-small Cell Lung Cancer | 08/25 | 10/25 | | |
NCT05826483: Almonertinib in the First-line Treatment of Patients of NSCLC With Poor Performance Status |
|
|
| Recruiting | 1 | 20 | RoW | Almonertinib | Guangzhou Institute of Respiratory Disease | Malignant Tumor of Lung, Poor Performance Status | 12/24 | 12/24 | | |
| chegnzhi, zhou |
NCT06341660: To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 2 | 30 | RoW | cadonilimab | Guangzhou Institute of Respiratory Disease | Non-small Cell Lung Cancer | 06/25 | 07/25 | | |
NCT06331650: A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 30 | RoW | cadonilimab | Guangzhou Institute of Respiratory Disease | Non-small Cell Lung Cancer | 08/25 | 10/25 | | |
NCT06310915: Oral Chemotherapeutic Drugs Were Analyzed in Patients With Driver Gene Negative Locally Advanced/Advanced Non-small Cell Lung Cancer With PS Score 2 A Prospective, Single-arm, Multicenter, Observational Study on the Efficacy and Safety of Radiochemotherapy Combined With PD-1 Inhibitor |
|
|
| Recruiting | N/A | 30 | RoW | Navelbine oral,Pembrolizumab | Guangzhou Institute of Respiratory Disease | Non-small Cell Lung Cancer Stage IIIB/IV | 03/25 | 05/25 | | |
